---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-202719"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2022-07-27T23:59:59+00:00"
generated_at: "2026-06-24T08:16:26.899335+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AlloVir raises $126.6M in registered direct offering at $4.61/share for Phase 3 trials

## Summary
- Sold 27.46M shares at $4.61 each; gross proceeds ~$126.6M.
- Funds to complete enrollment and data readouts in three ongoing Phase 3 trials of posoleucel.
- New investors include Kite (Gilead), F2 Ventures, ElevateBio, Invus, Redmile, EcoR1 Capital, GMT Capital.
- Offering expected to close July 28, 2022; no underwriter. Cash & equivalents $172.7M as of June 30, 2022.

## SEC filing metadata
- accession: 0001193125-22-202719
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2022-07-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312522202719/0001193125-22-202719-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312522202719/d286495d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-202719
- JSON: https://secwatch.observer/filing/0001193125-22-202719.json
- Plain text: https://secwatch.observer/filing/0001193125-22-202719.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.